S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial. (October 2021) - Khanna, Sahil; Kelly, Colleen R.; Louie, Thomas; Fisher, Monika; Hota, Susy; Misra, Bharat; Van Hise, Nicholas W.; Yen, Eugene F.; Bullock, Jeff S.; Pullman, John; Nathan, Richard; Silverman, Michael; et al.